Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Sanofi ( (SNY) ) is now available.
In April 2025, Sanofi announced that the US FDA granted orphan drug designation to rilzabrutinib for two rare diseases, warm autoimmune hemolytic anemia (wAIHA) and IgG4-related disease (IgG4-RD), which currently have no approved treatments. This designation underscores Sanofi’s commitment to addressing unmet medical needs in rare diseases. Rilzabrutinib, an investigational BTK inhibitor, is also under regulatory review for immune thrombocytopenia (ITP) in the US, EU, and China, with a target FDA decision date set for August 29, 2025. The drug has shown promising results in clinical trials, indicating its potential as a first- and best-in-class treatment for multiple immune-mediated diseases.
More about Sanofi
Sanofi is an innovative global healthcare company focused on transforming the practice of medicine by developing potentially life-changing treatment options and life-saving vaccines. The company is committed to sustainability and social responsibility, providing healthcare solutions to millions worldwide. Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY.
YTD Price Performance: 13.34%
Average Trading Volume: 2,611,473
Technical Sentiment Signal: Strong Sell
Current Market Cap: $135.2B
For detailed information about SNY stock, go to TipRanks’ Stock Analysis page.